Aldeyra Therapeutics (ALDX) Non-Current Deffered Revenue (2023 - 2026)

Aldeyra Therapeutics' Non-Current Deffered Revenue history runs 4 years deep, the most recent figure standing at $6.0 million for Q1 2026.

• Quarterly Non-Current Deffered Revenue changed 0.0% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (changed 0.0% YoY) and the FY2025 annual result came in at $6.0 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue was $6.0 million for Q1 2026 at Aldeyra Therapeutics, roughly flat from $6.0 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $6.0 million in Q4 2023 and bottomed at $6.0 million in Q4 2023.
• A 4-year average of $6.0 million and a median of $6.0 million in 2023 frame the typical range for Non-Current Deffered Revenue.
• Peak annual rise in Non-Current Deffered Revenue reached 0.0% in 2024, while the deepest fall reached 0.0% in 2024.
• Aldeyra Therapeutics' Non-Current Deffered Revenue stood at $6.0 million in 2023, then changed by 0.0% to $6.0 million in 2024, then changed by 0.0% to $6.0 million in 2025, then changed by 0.0% to $6.0 million in 2026.
• Business Quant data shows ALDX's Non-Current Deffered Revenue at $6.0 million in Q1 2026, $6.0 million in Q4 2025, and $6.0 million in Q3 2025.